SCHEMBL3008299

SCHEMBL3008299

O=S(=O)(c1ccc(Br)cc1)N1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.70
ALDH1A1 P00352 3/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
RAB9A P51151 4/20 0.57
MAPT P10636 7/20 0.55
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
MAPK1 P28482 5/20 0.55
LMNA P02545 5/20 0.55
NPC1 O15118 3/20 0.55
HPGD P15428 1/20 0.54
ALOX5 P09917 1/20 0.53
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011743 0.94 SMN1; SMN2 (0.78) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3011304 0.90 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3009735 0.89 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3022487 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3010921 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3017671 0.89 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3018895 0.89 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3014249 0.89 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL3017643 0.89 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL2557151 0.89 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1L3MBTL1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.